Lupin : May 15, 2024 Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office

Mumbai, May 15, 2024: Global pharma major Lupin Limited (Lupin) today announced that all 12 of its manufacturing sites, its R&D Center and corporate office in India have successfully completed rigorous audits and been certified by DNV for ISO 14001 - Environment Management Systems (EMS), and ISO 45001 - Occupational Health and Safety Management System (OHSMS).This achievement marks a significant milestone in acknowledging Lupin's commitment to safe and sustainable operations.

ISO14001is an internationally recognized standard for Environmental Management Systems. This certification demonstrates Lupin's dedication to minimizing its environmental footprint and fostering sustainable practices across its operations. The ISO 45001 certification underscores Lupin's unwavering commitment to ensuring the health, safety and well-being of its employees and stakeholders.

Commenting on this remarkable achievement, Nilesh Gupta, Managing Director, Lupin, said, "We are very proud of this achievement; it acknowledges our steadfast commitment to excellence in environmental stewardship and workplace safety and is a reflection of our ongoing efforts to integrate sustainable practices into our business operations and prioritize the health and safety of our people."

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.8% of its revenue in research and development in FY24.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on:
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: https://www.facebook.com/LupinWorld/
Twitter: https://twitter.com/LupinGlobal

For further information or queries, please contact:

Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
Email: [e-mail]

80